Compare Davita Inc (DVA) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Tyson Foods, Inc. — how do they compare? Davita Inc trades at $230.54 (market cap $14.92B), while Tyson Foods, Inc. trades at $57.96 (market cap $20.24B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.55% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TSN | |
|---|---|---|
Market Cap | $14.92B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $235.71 | $68.75 |
52-Week Low | $103.87 | $50.72 |
Enterprise Value | $27.47B | $27.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Tyson Foods (TSN) trades at $57.92, up 0.16% on the day, with a bearish technical signal but mixed earnings performance including a Q1 2026 beat. The company shows modest revenue growth to $54.44 billion in 2025, though net margins are thin at 0.81%. Recent news highlights innovation in prepared foods and new leadership appointments, while analyst consensus leans bullish with a $68.80 price target.
The stock presents a value opportunity with low P/S and P/B ratios, but faces risks from volatile earnings, high debt, and competitive pressures. Upside depends on execution in value-added segments and cost management, with the current price offering a 19% discount to the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
